Hangzhou DiShi Medical Biotechnology Co., Ltd. has recently announced the successful completion of nearly 100 million yuan in Series A funding, led by Plin Capital, with additional investments from Shangcheng Capital, Jinhe Capital, and other prominent institutions. The proceeds from this funding round will be primarily allocated towards accelerating the registration and clinical processes of microsurgical robots, as well as facilitating the commercialization of ophthalmic surgical robot products. DiShi Medical boasts an impressive portfolio of Chinese and US invention patents, and its ophthalmic surgical robot has attained the distinction of being the first product from China to be included in the NMPA's "Green Channel" for special review of innovative medical devices.

The company is dedicated to providing precise treatment solutions for the over 40 million patients suffering from fundus diseases in China. DiShi Medical has achieved significant technological breakthroughs in the realm of microsurgery, aiming to elevate the safety and precision of surgical procedures. With this new infusion of capital, the company is poised to further its mission of advancing medical care through innovative robotic technology.